VBI Vaccines, Inc. – (NASDAQ:VBIV) was the target of a large drop in short interest in December. As of December 15th, there was short interest totalling 365,691 shares, a drop of 43.9% from the November 30th total of 652,051 shares. Based on an average trading volume of 363,395 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.9% of the company’s stock are short sold.
Several equities analysts recently weighed in on the company. Zacks Investment Research lowered VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. BidaskClub lowered VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. BMO Capital Markets assumed coverage on VBI Vaccines in a research note on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price target for the company. Finally, Canaccord Genuity assumed coverage on VBI Vaccines in a research note on Wednesday, November 1st. They issued a “buy” rating and a $10.00 price target for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $8.75.
VBI Vaccines (VBIV) opened at $4.26 on Thursday. The firm has a market capitalization of $279.46, a P/E ratio of -5.84 and a beta of 1.75. VBI Vaccines has a twelve month low of $3.04 and a twelve month high of $6.60. The company has a current ratio of 1.03, a quick ratio of 0.97 and a debt-to-equity ratio of 0.19.
In other news, major shareholder Opko Health, Inc. bought 655,738 shares of VBI Vaccines stock in a transaction that occurred on Monday, October 30th. The stock was bought at an average price of $3.05 per share, for a total transaction of $2,000,000.90. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive bought 3,100,000 shares of VBI Vaccines stock in a transaction that occurred on Thursday, October 26th. The stock was purchased at an average price of $3.05 per share, with a total value of $9,455,000.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,080,738 shares of company stock worth $12,480,151 in the last ninety days. Insiders own 34.10% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System acquired a new position in VBI Vaccines in the second quarter valued at approximately $167,000. Schwab Charles Investment Management Inc. purchased a new stake in VBI Vaccines in the second quarter valued at approximately $187,000. Bank of New York Mellon Corp purchased a new stake in VBI Vaccines in the second quarter valued at approximately $193,000. Teachers Advisors LLC purchased a new stake in VBI Vaccines in the second quarter valued at approximately $195,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in shares of VBI Vaccines during the second quarter worth $262,000. Hedge funds and other institutional investors own 20.93% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/vbi-vaccines-inc-vbiv-short-interest-update.html.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.